Predict how fast an oral tablet releases its active pharmaceutical ingredient (API) in dissolution medium, using the Noyes-Whitney equation and Hixson-Crowell cube-root law. Tune particle radius, solubility, agitation and USP apparatus, and read off the total surface area, rate constant, t50, 30-min release, sink-condition status and USP acceptance in real time.
Parameters
Tablet dose
mg
Particle radius a
μm
Mean radius of the primary API crystals — smaller means more surface area and faster dissolution.
Diffusivity D
m²/s
Aqueous diffusion coefficient of a small-molecule API. Typical value ~5×10⁻¹⁰ m²/s.
Solubility C_s
mg/L
Saturation solubility in the test medium. Low for BCS Class II/IV.
Medium volume V
L
USP test volume. Standard values are 500, 900, 1000 mL.
Agitation
rpm
Paddle/basket speed. Affects the diffusion boundary layer thickness.
USP apparatus
Standard apparatus from USP <711>.
Target time
min
IR tablet standard: Q ≥ 80% at 30 min.
Results
—
Particle count N
—
Total area A (m²)
—
Rate constant k (1/s)
—
t50 (min)
—
Released at target (%)
—
USP (Q≥80% @30 min)
—
Vessel cross-section — paddle, particles and boundary layer
A USP II paddle stirs the medium; API diffuses out of each particle through its stagnant boundary layer. The right strip shows a mock UV-absorbance trace at 254 nm.
Dissolution profile — cumulative release vs time (Hixson-Crowell)
First-order approximation of the dissolution rate constant and 50% release time. V is the dissolution medium volume (m³); N and A are derived from dose and particle radius.
If the dose-to-volume ratio is below one-fifth of solubility, the driving force (C_s − C) is essentially constant. Engineering this condition is at the heart of BCS Class II/IV formulation design.
Tablet dissolution — the Noyes-Whitney equation and USP tests
🙋
Why do we even run dissolution tests? Doesn't a tablet just dissolve in the stomach on its own?
🎓
Great question. For an oral tablet to reach the bloodstream there are three steps — dissolve, cross the gut wall, survive first-pass metabolism — and the dissolution step is the bottleneck for most molecules. So before going anywhere near a patient, we measure in the lab "how fast does the API come out?" in a reproducible way. That's USP <711> Dissolution. The default IR acceptance is "Q ≥ 80% dissolved within 30 minutes".
🙋
OK. So what actually controls that rate? The Noyes-Whitney equation dM/dt = D·A·(C_s − C)/h has a lot of moving parts.
🎓
The classical 1897 equation, yes. The two biggest levers are A (surface area) and C_s (saturation solubility). Halve the particle radius and the surface area quadruples, so k_dissol quadruples. That's why poorly soluble compounds get jet-milled, nanonised or formulated as amorphous solid dispersions — anything to push A and apparent C_s up. If C_s is intrinsically tiny (BCS Class II/IV), more stirring barely helps and you need formulation engineering.
🙋
If I drop solubility from 1000 to 200 mg/L on the slider, the box turns orange ("warn"). What's that?
🎓
That's the "sink condition" warning. 250 mg in 0.9 L gives ~278 mg/L, which already exceeds the solubility of 200 mg/L — there is no way the dose can fully dissolve. The USP rule of thumb is dose/V < 0.2·C_s; otherwise the bulk concentration saturates and the curve plateaus, masking the true formulation behaviour. Standard fixes are larger media volume, surfactant (SLS 0.1-1%), buffered media at favourable pH, or switching to USP IV flow-through.
🙋
How do you decide between USP I, II and IV? The drop-down changes t50 a bit.
🎓
II (paddle, 50-100 rpm) covers roughly 80% of marketed products. I (basket, ~100 rpm) is for floating tablets or capsules. IV (flow-through) is the choice for poorly soluble drugs, sustained-release products, implants and suppositories. The main effect on the model is the boundary-layer thickness h: more agitation, thinner layer, larger k. This tool uses h ≈ 30 µm for II, ≈ 40 µm for I, ≈ 20 µm for IV. For bioequivalence (BE) studies, you must match the reference product's apparatus and demonstrate similarity with the f2 factor ≥ 50.
🙋
One last thing — at the default settings I see "Q=100% at 30 min, USP OK, but warn". Is that pass or fail?
🎓
Pass on paper, but unreliable in practice — the sink condition is violated, so that "100%" is partly the bulk saturating, not real release. You would re-run with adjusted conditions before trusting it. Conversely, shrinking the radius to 10 µm leaves the sink violation untouched but makes k so large that 100% is hit safely. Whether you change the formulation or the test depends on the goal: for BE, conditions are fixed and you tune the formulation; in pre-formulation, both knobs are on the table.
Frequently asked questions
The Noyes-Whitney equation dM/dt = D·A·(C_s − C)/h (Noyes & Whitney, 1897) describes the dissolution rate of a solid into a liquid. D is the diffusion coefficient, A the particle surface area, C_s the saturation solubility, C the bulk concentration and h the diffusion boundary-layer thickness. Under sink conditions (C ≪ C_s) the driving force is constant, otherwise it decays as C rises. This simulator combines that equation with the Hixson-Crowell cube-root law to predict the full tablet dissolution profile.
USP I (basket) suits capsules or tablets that float, USP II (paddle, the workhorse) is used for most immediate- and modified-release tablets, and USP IV (flow-through cell) is preferred for poorly soluble drugs, sustained-release products and implants. II runs at 50-100 rpm, I around 100 rpm. USP <711> sets media volume at 500-1000 mL and 37 °C. Switching apparatus in this tool changes the effective boundary-layer thickness h and therefore the rate constant k_dissol and t50.
When the sink condition C < 0.2·C_s holds, dissolution is limited only by mass transport at the particle surface, giving reproducible tests. If dose/volume exceeds 1/5 of C_s, the bulk concentration approaches C_s and the curve plateaus prematurely — the true performance of the formulation cannot be evaluated. This simulator detects the violation automatically and suggests larger media volume, surfactant addition or the use of USP IV. For BCS Class II/IV drugs, engineering sink with surfactants (SLS 0.1-1%) or buffer pH is standard practice.
The Biopharmaceutics Classification System groups APIs by solubility and intestinal permeability into four classes. Class I (high/high, e.g. acetaminophen) — dissolution does not limit absorption and BE waivers are straightforward. Class II (low/high, e.g. ibuprofen) — dissolution is rate limiting, so particle-size reduction, solid dispersions or salt selection are essential. Class III (high/low) — permeability enhancement. Class IV (low/low, e.g. some furosemide salts) is the hardest case and usually requires in-vivo studies.
Real-world applications
Quality control of immediate-release (IR) tablets: consumer-health products such as acetaminophen, ibuprofen and loxoprofen are released on the market against an USP II paddle test with Q ≥ 80% at 30 min. Lot-to-lot variation in particle-size distribution shifts k_dissol and can fail the Q criterion. Use this tool to scan "what if my milling outputs 100 µm instead of 50 µm?" before locking the upper limit of your particle-size specification.
Bioequivalence (BE) comparison for generics: generic approval typically requires showing that the test product's dissolution curve is "similar" to the originator's, with the f2 similarity factor ≥ 50, in three media (pH 1.2, 4.0 and 6.8) with 12 units each. A non-sink condition will inflate f2 artificially, so the automatic sink check here is a useful pre-screening for protocol design.
Formulation strategy for poorly soluble (BCS II) drugs: itraconazole, fenofibrate and griseofulvin are textbook cases. Micronisation (<5 µm), nanocrystal technology (<200 nm) and spray-dried amorphous solid dispersions all aim to boost A and effective C_s. Drop the radius from 50 µm to 1 µm in the slider and watch k_dissol explode — that intuitive sensitivity is exactly why pharma companies invest in jet mills and spray dryers.
Sustained-release (SR/CR) products: with hydrophilic matrix tablets or coated multiparticulates the rate-limiting step is matrix diffusion, not surface dissolution. The first-order model here is tuned for IR, but by adjusting k_dissol and volume you can get a rough 0-24 h release envelope. Combining the simulation with USP IV flow-through tests lets you reproduce in-vivo-like "always-sink" conditions in the laboratory.
Common misconceptions and caveats
The biggest trap is using non-sink data to claim BE. When dose/V ≥ 0.2·C_s, bulk concentration saturates and the curve hits an artificial plateau; even "100% at 30 min" can mean the medium simply ran out of solvent, not that the product would release that well in vivo (where V is effectively infinite and sink holds permanently). FDA, EMA and PMDA all require sink conditions for BE submissions. Try, in order: increase media to 1 L+, add surfactant (SLS 0.1-1%), or switch to USP IV flow-through.
The next trap is blindly applying the Hixson-Crowell cube-root law to every product. Cube-root kinetics M(t)^(1/3) = M_0^(1/3) − k·t assumes spherical particles that shrink with constant shape, no aggregation/coalescence and no polymorphic transition. Real formulations show lag time as the disintegrant releases the API, or Ostwald's rule where a metastable polymorph slowly converts to a less soluble stable form during the test. Treat this simulator as a first-pass approximation and fit experimental curves with Weibull or Korsmeyer-Peppas before drawing conclusions.
The third trap is "smaller is always better". Yes, A scales with 1/r and k_dissol rises, but below ~500 nm Ostwald ripening (small particles re-dissolve onto larger ones) becomes severe, so particle-size distribution and dissolution drift in storage. Manufacturability also degrades: dust-explosion risk, poor flow, tablet weight scatter and static cling all increase. The pragmatic optimum is often 5-20 µm, complemented by crystallisation inhibitors (HPC, PVP K30) and a "spring and parachute" strategy that transiently sustains a supersaturated solution rather than relying on raw particle size alone.
How to Use
Enter tablet dose in mg (typical range 50–1000 mg for oral APIs) and particle radius in micrometers (1–100 μm affects surface area exponentially)
Input diffusivity (cm²/s, typically 10⁻⁶–10⁻⁵ for aqueous solutions) and saturation solubility (mg/L, critical for sink conditions)
Run simulation to calculate Noyes-Whitney rate constant k, time to 50% release (t₅₀), and compliance with USP Apparatus 2 dissolution targets (≥80% at 30 min)
Worked Example
Ibuprofen tablet: 200 mg dose, 15 μm mean particle radius, D = 8×10⁻⁶ cm²/s, solubility 21 mg/L in pH 6.8 phosphate buffer. Noyes-Whitney equation dC/dt = (DA/h)(Cs − C) yields surface area A ≈ 1.13 m², rate constant k ≈ 0.0082 min⁻¹, t₅₀ ≈ 84 min. At 30 min, approximately 19% released under these conditions, failing USP Q requirement. Reducing particle size to 5 μm increases A to 10.2 m², k to 0.073 min⁻¹, achieving 47% at 30 min.
Practical Notes
Sink condition critical: maintain C << Cs by using sufficient medium volume; if solubility ≤10 mg/L, dissolution becomes solubility-limited rather than diffusion-limited
Micronization and surfactant addition (e.g., polysorbate 80, sodium lauryl sulfate) increase effective solubility and D, accelerating release—essential for BCS Class II compounds
Temperature and pH alter both D and Cs; USP specifies 37°C, pH 1.2–7.5 depending on dosage form intent and GI transit
Particle radius dominates: halving radius increases total surface area 4-fold, dramatically reducing t₅₀ and improving bioavailability